2022
COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit
Kumar N, Corpus I, Hans M, Harle N, Yang N, McDonald C, Sakai SN, Janmohamed K, Chen K, Altice FL, Tang W, Schwartz JL, Jones-Jang SM, Saha K, Memon SA, Bauch CT, Choudhury M, Papakyriakopoulos O, Tucker JD, Goyal A, Tyagi A, Khoshnood K, Omer S. COVID-19 vaccine perceptions in the initial phases of US vaccine roll-out: an observational study on reddit. BMC Public Health 2022, 22: 446. PMID: 35255881, PMCID: PMC8899002, DOI: 10.1186/s12889-022-12824-7.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine perceptionsVaccine perceptionsCOVID-19 vaccination servicesVaccine trial dataUS vaccineDevelopment of interventionsVaccine trialsVaccination servicesObservational studyVaccine informationTrial dataVaccineConclusionsOur findingsVaccine-related keywordsCOVID-19Vaccine misinformationEarly phaseInitial phaseAssociationFurther researchCommunication campaignsVaccinationResultsTherePrevalenceMethodsWe
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screeningInterventions to Mitigate COVID-19 Misinformation: A Systematic Review and Meta-Analysis
Janmohamed K, Walter N, Nyhan K, Khoshnood K, Tucker JD, Sangngam N, Altice FL, Ding Q, Wong A, Schwitzky ZM, Bauch CT, De Choudhury M, Papakyriakopoulos O, Kumar N. Interventions to Mitigate COVID-19 Misinformation: A Systematic Review and Meta-Analysis. Journal Of Health Communication 2021, 26: 846-857. PMID: 35001841, DOI: 10.1080/10810730.2021.2021460.Peer-Reviewed Original ResearchResponse
Price CC, Altice FL, Azar MM, McManus D, Gleeson SE, Britto CJ, Azmy V, Kaman K, Davis M, Chupp G, Bucala R, Kaminski N, Topal JE, Dela Cruz C, Malinis M. Response. CHEST Journal 2021, 159: 2116-2117. PMID: 33965143, PMCID: PMC8097398, DOI: 10.1016/j.chest.2020.12.032.Commentaries, Editorials and Letters
2020
Response to the COVID-19 Outbreak in Urban Settings in China
Ni Z, Lebowitz ER, Zou Z, Wang H, Liu H, Shrestha R, Zhang Q, Hu J, Yang S, Xu L, Wu J, Altice FL. Response to the COVID-19 Outbreak in Urban Settings in China. Journal Of Urban Health 2020, 98: 41-52. PMID: 33258088, PMCID: PMC7703725, DOI: 10.1007/s11524-020-00498-8.Peer-Reviewed Original ResearchTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes